
Morepen Laboratories Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Targeting INR 5,000 crores revenue by 2030 with ~20% CAGR (currently achieving ~18.9% CAGR).
- Medical devices expected to grow faster than pharma, shifting revenue mix to about 40% devices and 60% pharma by 2030.
- Focus on profitable growth by reducing low-yielding domestic API business and expanding high-value items.
- Pharmaceutical exports growing robustly, with Europe up 60% and US up 5%; domestic market reduced to maintain margins.
- Medical devices installed base increased from 10.5 million to 13 million meters yearly; strip consumption per meter is rising.
- Capacity expansions underway in API (from 400 KL to 600 KL) and formulations to support growth.
- New product launches planned in devices (e.g., Bluetooth meters) and medical devices expansion including nebulizers and ortho support.
- Expect stronger growth in H2 compared to H1 FY25, with improved capacities now stabilizing.
See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.
Fundraise plans
YesSee what Morepen Laboratories management said on order book — free account, 30 seconds.
Capex plans
Yes- Morepen Laboratories has ongoing expansion plans funded by a recent QIP with INR123 crores allocated for capex.
- Expansion includes three production blocks (P8, P9, P10) with civil and machinery work underway; P8 nearing completion.
- API capacity is being increased from 400 KL to 600 KL, with 50 KL already implemented and 15% production increase expected soon.
- Finished dosage facility in Baddi is commissioned, capable of 1.2 billion dosages, with validations in process to start booking orders within 12-18 months.
- Focus on expanding medical devices segment with new products like nebulizers and ortho support, and plans to unlock value in medical devices and branded formulations.
- QIP proceeds utilized for capex, working capital, and ongoing investments; INR137 crores still available as of Sept 30, 2024.
- The strategic shift aims to reposition Morepen from a B2B to a more consumer-facing B2C company for better returns and brand value.
Track Morepen Laboratories — get its next earnings analysis in your feed
How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?
Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem